Home » Stocks » RUBY

Rubius Therapeutics, Inc. (RUBY)

Stock Price: $26.15 USD 1.09 (4.35%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 2.30B
Revenue (ttm) n/a
Net Income (ttm) -167.73M
Shares Out 80.62M
EPS (ttm) -2.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $26.15
Previous Close $25.06
Change ($) 1.09
Change (%) 4.35%
Day's Open 25.14
Day's Range 25.14 - 26.44
Day's Volume 299,063
52-Week Range 4.20 - 38.71

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...

3 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...

4 weeks ago - GlobeNewsWire

Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest ...

Other stocks mentioned: BMY, PFE, BCRX, MRKR, PCRX, PRQR, ZEAL
1 month ago - Benzinga

Here's why these attention-grabbing stocks could be toxic to your portfolio.

Other stocks mentioned: OCGN, SAVA
1 month ago - The Motley Fool

Investors need to pay close attention to Rubius Therapeutics (RUBY) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

CAMBRIDGE Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ: RUBY) (“Rubius”), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cre...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ: RUBY) (“Rubius”), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cr...

1 month ago - GlobeNewsWire

Rubius Therapeutics Inc (NASDAQ: RUBY) stock is trading after reporting initial data from its ongoing Phase 1/2 trial of RTX-240 in patients with advanced solid tumors. Initial efficacy results showed a...

1 month ago - Benzinga

The company announced positive results from a clinical trial.

1 month ago - The Motley Fool

Rubius Therapeutics (RUBY) stock was flying high on Monday after announcing early results from a clinical trial of its new cancer treatment. The post RUBY Stock Alert: The Promising Cancer Drug News Tha...

1 month ago - InvestorPlace

RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse Events

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., March 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ent...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

Other stocks mentioned: AXLA, CDAK, DNLI, EVLO, FHTX, KLDO, MCRB ...
2 months ago - PRNewsWire

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...

3 months ago - GlobeNewsWire

Rubius has an interesting science hypothesis, however it failed a first proof of concept trial. It is now running its next one. They have adequate cash for the time being.

3 months ago - Seeking Alpha

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entir...

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entir...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entir...

5 months ago - GlobeNewsWire

Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2  Solid Tumor Clinical Trial

5 months ago - GlobeNewsWire

RTX-240 Demonstrates Promotion of T Cell and Natural Killer Cell Activation and Expansion In Vitro and In Vivo RTX-240 Demonstrates Promotion of T Cell and Natural Killer Cell Activation and Expansion I...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entir...

6 months ago - GlobeNewsWire

RTX-321 Induces Antigen-Specific Stimulation Combined with Broad Stimulation of Innate and Adaptive Immune Responses RTX-321 Induces Antigen-Specific Stimulation Combined with Broad Stimulation of Innat...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an en...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an en...

7 months ago - GlobeNewsWire

These biotechs have a long road ahead, but they just might deliver massive growth.

Other stocks mentioned: JNCE, SRNE
7 months ago - The Motley Fool

CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an en...

7 months ago - GlobeNewsWire

Strong Momentum in Dosing Patients and Manufacturing Clinical Supply for  RTX-240 Phase 1/2 Solid Tumor Clinical Trial

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ent...

9 months ago - GlobeNewsWire

Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: ISEE, ZYNE
10 months ago - Seeking Alpha

CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ent...

10 months ago - GlobeNewsWire

RTX-321 May Induce Epitope Spreading and Long-Term Tumor Memory RTX-321 May Induce Epitope Spreading and Long-Term Tumor Memory

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...

11 months ago - GlobeNewsWire

CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...

11 months ago - GlobeNewsWire

Completed Strategic Reprioritization of Pipeline to Focus on Oncology and Autoimmunity

11 months ago - GlobeNewsWire

CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ent...

1 year ago - GlobeNewsWire

Rubius Therapeutics' (RUBY) CEO Pablo Cagnoni on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ent...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ent...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ent...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ent...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an en...

1 year ago - GlobeNewsWire

About RUBY

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
IPO Date
Jul 18, 2018
CEO
Pablo Cagnoni
Employees
204
Stock Exchange
NASDAQ
Ticker Symbol
RUBY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for RUBY stock is "Buy." The 12-month stock price forecast is 30.20, which is an increase of 15.49% from the latest price.

Price Target
$30.20
(15.49% upside)
Analyst Consensus: Buy